Gemcitabine News and Research

RSS

Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite

Two new clinical trials show promise for basal cell carcinoma and pancreatic cancer

Clinical researchers at Scottsdale Healthcare and TGen have announced the results of two clinical trials that show promise for patients battling cancer.

16 Apr 2008

Global Alliance for Pharmacogenomics

Leaders at the National Institutes of Health and the Center for Genomic Medicine in Japan have signed a letter of intent creating a Global Alliance for Pharmacogenomics.

15 Apr 2008

Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers

Recurrent low-grade serous carcinoma, a rare type of ovarian cancer, is less sensitive to chemotherapy and therefore more difficult to treat than more common high-grade ovarian cancers, according to researchers from The University of Texas M. D. Anderson Cancer Center.

11 Mar 2008

Chemotherapy with chemoradiation for pancreatic cancer has small survival benefit

The addition of the drug gemcitabine with chemoradiation for the treatment of patients who had surgery for pancreatic cancer was associated with a survival benefit, although this improvement was not statistically significant, according to a study in the March 5 issue of JAMA.

6 Mar 2008

Study confirms safety of BrachySil for treatment of inoperable pancreatic cancer

The results of a Phase IIa clinical trial of BrachySil for the treatment of advanced, inoperable pancreatic cancer were presented at American Society of Clinical Oncolgy-GI (ASCO-GI) this weekend in a poster presented by Dr. Paul Ross, Chief Investigator in the study and Consultant Medical Oncologist at Guy's and St. Thomas' NHS Foundation Trust.

30 Jan 2008

Study may aid pancreatic cancer patients' response to chemo drugs

Pancreatic cancer patients face the worst survival rates compared to all other forms of human cancer as the disease is nearly impossible to diagnose at an early stage when successful treatments might be possible.

1 Nov 2007

New treatment option studied for bladder cancer

A chemotherapy regimen for patients with advanced bladder cancer who aren't eligible for standard treatment is under study at the Medical College of Georgia.

29 Oct 2007

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

Chemotherapy drug gemcitabine delays progression of operable pancreatic cancer

Barcelona, Spain: Giving pancreatic cancer patients the chemotherapy drug gemcitabine after surgery delays progression of the disease by about six months, according to new research by Japanese scientists.

27 Sep 2007

Avastin approved in Europe for advanced lung cancer

Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.

26 Aug 2007

Lung cancer patients taking Tarceva who develop a rash fair better

The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug's developer, OSI Pharmaceuticals, Inc.

4 Jul 2007

Skin rash actually signifies better outcomes for pancreatic and lung cancer patients

The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug's developer, OSI Pharmaceuticals, Inc.

3 Jul 2007

Levels of protein CA 19-9 in blood predicts pancreatic cancer outcome after surgery

A team of researchers, led by surgeons at the Kimmel Cancer Center at Jefferson in Philadelphia, has found further evidence supporting the ability of a protein to predict how well a patient with advanced pancreatic cancer will do after surgery, chemotherapy and radiation.

23 Jun 2007

Studies try to shed light on impact of race

Statistics show lung cancer is the leading cause of cancer death in African-Americans, with 21,550 new cases expected to be diagnosed and 16,700 deaths expected this year.

3 Jun 2007

Oncolytic viruses deliver a knockout punch to cancers

New scientific evidence is helping to build a compelling case for oncolytic viruses as a first-line and adjunctive treatment for many cancers.

11 May 2007

Tarceva extends life of patients with pancreatic cancer

New results published by the Journal of Clinical Oncology show that adding Tarceva (erlotinib) to gemcitabine chemotherapy significantly improves survival by 22 percent in patients with advanced pancreatic cancer.

27 Apr 2007

Oncolytics Biotech researchers demonstrate reovirus/gemcitabine

Oncolytics Biotech announced that a poster by Dr. Maureen E. Lane et al. of Cornell University, New York , entitled "In Vivo Synergy between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116 Xenografts" was presented at the American Association for Cancer Research (AACR) Annual Meeting in Los Angeles, CA.

18 Apr 2007

Early stage pancreatic cancer expresses antigen targeted by Immunomedics' PAM4 antibody

Immunomedics has reported in an oral presentation at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) that the antigen targeted by the humanized PAM4 antibody is expressed in early stage pancreatic cancer specimens, a stage before the tumor becomes invasive.

18 Apr 2007

Curcumin has anticancer effects

Curry powder is a mixture predominantly composed of turmeric root extract and other spices such as coriander and fenugreek.

14 Apr 2007

Massive gene screening points way to more effective chemotherapy

Using a technology that can quickly screen all 20,000-plus human genes for biological activity, scientists have isolated 87 genes that seem to affect how sensitive human cancer cells are to certain chemotherapy drugs.

12 Apr 2007